MAR (6 7: 03

EDOCKET NO.:TJU-2412

TECH CENTER 1600/2980 TENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Scott A. Waldman, et al.

Serial No.: 09/819,249

Group Art Unit: 1637

Filed: March 27, 2001

Examiner: Alexander H. Spiegler

For:

COMPOSITIONS AND METHODS FOR IDENTIFYING AND TARGETING CANCER CELLS OF ALIMENTARY CANAL ORIGIN

> EXPRESS MAIL LABEL NO .: EL 926696185 US DATE OF DEPOSIT: February 25, 2003

Assistant Commissioner for Patents

Washington, D.C. 20231

REPLY UNDER 37 C.F.R. § 1.143 TO OFFICE ACTION DATED SEPTEMBER 26, 2002

Reconsideration of the requirement for restriction is respectfully requested in view of the following remarks.

Restriction Requirement

A restriction has been required under 35 U.S.C. § 121 to one of eight groups of inventions, characterized as Groups I to VIII. The claims and the subject matter said to be associated with each group are set forth below.

Group L encompassing claims 1-28 (in part), drawn to methods of screening or

Group II, encompassing claims 1-24 (in part) and 29-32, drawn to methods of screening or diagnosing an individual suspected of having primary and/or metastatic esophageal cancer;

2

Group III, encompassing claim 33, drawn to a kit comprising primers;

Group IV, encompassing claim 33, drawn to a kit comprising antibodies;

Group V, encompassing claims 34 to 36 (in part), drawn to methods of treating primary and/or metastatic stomach cancer with an ST receptor ligand and an active agent;

Group VI, encompassing claims 34 to 36 (in part), drawn to methods of treating primary and/or metastatic esophageal cancer with an ST receptor ligand and an active agent;

Group VII, encompassing claims 37-38 (in part), drawn to methods of radioimaging primary and/or metastatic stomach cancer; and

Group VIII, encompassing claims 37-38 (in part), drawn to methods of radioimaging primary and/or metastatic esophageal cancer.

The Office Action asserts that the inventions of Groups I to VIII are patentably distinct. Applicants respectfully traverse the restriction requirement as it applies to Groups I and II.

Applicants respectfully request the Examiner to consider reconfiguring the restriction requirement so that the subject matter of Groups I and II is contained within a single group. Applicants respectfully submit that the relationship among the subject matter defined by the present claims is such that a reasonable search of the methods defined by the claims of Group I would necessarily lead to disclosures, to the extent any exist, of the methods defined by the claims of Group II. Accordingly, Applicants respectfully submit that a search and

impose a serious burden on the Examiner

DOCKET NO.:TJU-2441

3

PATENT

In accordance with 37 CFR 1.143, applicants hereby provisionally elect for prosecution the subject matter of Group II, encompassing claims 1-24 (in part) and 29-32, and drawn to methods of screening or diagnosing an individual suspected of having primary and/or metastatic esophageal cancer.

Conclusion

Applicants believe that the foregoing constitutes a complete and full response to the Office Action of record. Accordingly, an early and favorable Action is respectfully requested.

Respectfully submitted,

Jan Lycuse

Jane E. Inglese, Ph.D. Registration No. 48,444

Date: **February 25, 2003**WOODCOCK WASHBURN LLP

One Liberty Place - 46th Floor Philadelphia, PA 19103

(215) 568-3100